Clinical Trial Update: Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating eslicarbazepine acetate as add-on therapy for refractory partial seizures reported efficacy and safety results; the study was sponsor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• eslicarbazepine acetate (eslicarbazepine acetate)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Refractory Partial Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2013-10-10